Blue Sky Health Sector Stock Volatility Report

Notable Movers & Volatility

The dispersion in this 31-name set was extreme: MRNA (+55.45%, $130.38 → $202.67) and TEM (+48.06%) sat nearly 100 percentage points above KPTI (-42.06%, $2.14 → $1.24), with QURE (-27.76%) and CDXS (-25.95%) also deeply negative.

Implied volatility repeatedly mispriced the realized move. SYK was the standout at 3.64x — a 30.81% implied vol against a -19.46% slide and 33.89% realized vol — followed by TEM (3.44x), MRNA (3.36x), AMGN (2.73x, realized 40.73% vs. implied 29.93%) and EBS (2.68x). At the other end, options looked richly priced on the highest-IV names: DBVT (260.16% implied, 0.29x), CDXS (278.13% implied, 0.42x), ADUS (0.61x), QURE (0.76x) and HUM (0.78x) all realized far less than their premiums suggested.

Closing location reinforced the trend: TEM finished at 98.52% of its range and MRNA at 94.77%, with LLY (84.07%) and EBS (83.55%) also near highs. Weakness was equally decisive — CNC closed at 6.68%, SYK 8.31%, ABT 8.83%, QURE 9.82% and ADUS 10.27%, all pinned near period lows.

Broader Market Context

Differential behavior within the sector. This was not a sector moving as one block. The defensive large-cap core was relatively contained — XLV fell just 5.37% with 14.87% realized vol, and JNJ (-7.25%), ABBV (+9.17%), MRK (+7.90%) and LLY (+7.59%) all realized volatility in the high-teens to mid-20s. The tails were an entirely different market: micro- and small-cap biotech and devices (KPTI 115.70% realized vol, STIM 69.56%, CDXS 57.06%, QURE 51.26%, DBVT 50.60%) traded with three-to-seven times the sector ETF's volatility. Managed care formed a third, distinctly weak cohort — CNC -12.04%, HUM -12.11%, CVS -14.21%, UNH -9.97%, CI -9.34% — while providers (THC -9.03%) and home health (ADUS -6.94%) sagged more modestly.

Rotation versus idiosyncratic risk. The pattern reads as mostly stock- and sub-industry-specific rather than a clean rotation into or out of health care. A defensive bid would typically lift the staples-like large caps together; instead, ABBV, MRK, GILD and LLY rose while ABT (-12.13%) and SYK (-19.46%) fell hard — hard to reconcile with a single macro impulse. The simultaneous, tightly clustered decline across five managed-care names is more consistent with a shared sub-sector re-rating, while the 40-55% moves in MRNA, TEM, KPTI and QURE are consistent with binary, name-level catalysts.

Plausible current drivers. Without asserting specific events, the data is consistent with several themes that commonly drive this sector:

• Policy and reimbursement uncertainty — the synchronized managed-care weakness (CNC closing at 6.68% of range, CVS at 33.07%) often accompanies concerns over medical cost trends, rate-setting or utilization.
• Clinical/regulatory binaries — triple-digit implied vols on DBVT (260%), CDXS (278%) and KPTI (219%) indicate the market was explicitly pricing event risk in small-cap biotech.
• Rate and risk-appetite sensitivity — long-duration, unprofitable biotech typically amplifies shifts in discount-rate expectations, which would help explain the gulf between XLV and the micro-cap tail.
• Selective growth bid — MRNA and TEM closing above 94% of range suggests targeted, not broad, sector inflows.